Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study-Reference-Cited by-同舟云学术

Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study

Published:2023-05 Issue:5 Volume:41 Page:252.e19-252.e27
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Lowentritt Benjamin,Pilon Dominic,Waters Dexter,Rossi Carmine^ORCID,Muser Erik,Kurteva Siyana,Shah Aditi,Khilfeh Ibrahim,Du Shawn,Ellis Lorie,Lefebvre Patrick,Brown Gordon

Funder

Janssen Scientific Affairs

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference24 articles.

1. Androgen receptor signaling in prostate cancer and therapeutic strategies;Jacob;Cancers,2021

2. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer;Armstrong;J Clin Oncol,2022

3. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer;Armstrong;J Clin Oncol,2019

4. Apalutamide for metastatic, castration-sensitive prostate cancer;Chi;N Engl J Med,2019

5. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study;Chi;J Clin Oncol,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors;Clinical Genitourinary Cancer;2024-10

2. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis;European Urology Oncology;2024-08

3. First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer;Die Urologie;2023-12-21